Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bruix, J. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, A. Craxì, P. Galle, A. Santoro, M. Beaugrand, A. Sangiovanni, C. Porta, G. Gerken, J. Marrero, A. Nadel, M. Shan, M. Moscovici, D. Voliotis, J. Llovet (2012)Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Journal of hepatology, 57 4
B. Houk, C. Bello, B. Poland, L. Rosen, G. Demetri, R. Motzer (2010)Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Cancer Chemotherapy and Pharmacology, 66
Olivier Belzile, Xianming Huang, J. Gong, J. Carlson, A. Schroit, R. Brekken, B. Freimark (2018)Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
ImmunoTargets and Therapy, 7
C. Fitzmaurice, M. Naghavi (2017)Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden-Reply.
JAMA oncology, 3 10
A. Beck, T. Luster, Andrew Miller, S. Holloway, Chris Conner, C. Barnett, P. Thorpe, J. Fleming, R. Brekken (2006)Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
International Journal of Cancer, 118
X Chen, K Doffek, SL Sugg, J Shilyansky (1950)Phosphatidylserine regulates the maturation of human dendritic cells
J Immunol Baltim Md, 2004
R. Kelley, G. Abou-Alfa, J. Bendell, Tae-You Kim, M. Borad, W. Yong, M. Morse, Yoon-Koo Kang, M. Rebelatto, M. Makowsky, Feng Xiao, S. Morris, B. Sangro (2017)Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.
Journal of Clinical Oncology, 35
A. Yopp, J. Mansour, M. Beg, J. Arenas, C. Trimmer, M. Reddick, I. Pedrosa, G. Khatri, Takeshi Yakoo, J. Meyer, Jacqueline Shaw, J. Marrero, A. Singal (2013)Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome
Annals of Surgical Oncology, 21
M Kudo, RS Finn, S Qin, K-H Han, K Ikeda, F Piscaglia (2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Lancet Lond Engl., 391
Yong Chang, J. Adnane, P. Trail, Joan Levy, A. Henderson, D. Xue, E. Bortolon, Marina Ichetovkin, Chen Chen, Angela Mcnabola, D. Wilkie, Christopher Carter, I. Taylor, M. Lynch, S. Wilhelm (2007)Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Cancer Chemotherapy and Pharmacology, 59
T. Nakazawa, H. Hidaka, Juichi Takada, Y. Okuwaki, Yoshiaki Tanaka, Masaaki Watanabe, A. Shibuya, Tsutomu Minamino, S. Kokubu, W. Koizumi (2013)Early increase in &agr;-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
European Journal of Gastroenterology & Hepatology, 25
S. Ran, Jin He, Xianming Huang, M. Soares, D. Scothorn, P. Thorpe (2005)Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice
Clinical Cancer Research, 11
Xianming Huang, M. Bennett, P. Thorpe (2005)A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
Cancer research, 65 10
O. Abdel-Rahman (2018)Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study
Journal of Cancer Research and Clinical Oncology, 144
Sabrina Riedl, B. Rinner, M. Asslaber, H. Schaider, S. Walzer, Alexandra Novak, K. Lohner, D. Zweytick (2011)In search of a novel target — Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy
Biochimica et Biophysica Acta, 1808
T. Yau, T. Yao, P. Chan, H. Wong, R. Pang, S. Fan, R. Poon (2011)The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
The oncologist, 16 9
T. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, J. Neal, Haolan Lu, J. Cuillerot, M. Reck (2012)Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 17
Xiao Chen, K. Doffek, S. Sugg, J. Shilyansky (2004)Phosphatidylserine Regulates the Maturation of Human Dendritic Cells1
The Journal of Immunology, 173
C. Fitzmaurice, Christine Allen, Ryan Barber, L. Barregard, Z. Bhutta, H. Brenner, D. Dicker, Odgerel Chimed-Orchir, R. Dandona, L. Dandona, T. Fleming, M. Forouzanfar, Jamie Hancock, Roderick Hay, Rachel Hunter-Merrill, Chantal Huynh, H. Hosgood, C. Johnson, J. Jonas, J. Khubchandani, G. Kumar, Michael Kutz, Q. Lan, H. Larson, Xiaofeng Liang, Stephen Lim, Alan Lopez, Michael MacIntyre, L. Marczak, N. Marquez, A. Mokdad, Christine Pinho, F. Pourmalek, J. Salomon, J. Sanabria, Logan Sandar, B. Sartorius, S. Schwartz, K. Shackelford, K. Shibuya, J. Stanaway, C. Steiner, Jiandong Sun, Ken Takahashi, S. Vollset, T. Vos, J. Wagner, Haidong Wang, R. Westerman, H. Zeeb, Leo Zoeckler, F. Abd-Allah, M. Ahmed, S. Alabed, N. Alam, Saleh Aldhahri, Girma Alem, Mulubirhan Alemayohu, R. Ali, Rajaa Al-Raddadi, A. Amare, Y. Amoako, A. Artaman, H. Asayesh, N. Atnafu, A. Awasthi, H. Saleem, A. Barać, Neeraj Bedi, I. Benseñor, A. Berhane, E. Bernabé, B. Betsu, A. Binagwaho, D. Boneya, Ismael Campos-Nonato, C. Castañeda-Orjuela, F. Catalá-López, P. Chiang, C. Chibueze, Abdulaal Chitheer, J. Choi, B. Cowie, S. Damtew, J. Neves, S. Dey, S. Dharmaratne, P. Dhillon, E. Ding, T. Driscoll, D. Ekwueme, A. Endries, M. Farvid, F. Farzadfar, João Fernandes, F. Fischer, Tsegaye G/hiwot, A. Gebru, S. Gopalani, A. Hailu, M. Horino, N. Horita, A. Husseini, I. Huybrechts, M. Inoue, F. Islami, M. Jakovljevic, S. James, Mehdi Javanbakht, S. Jee, A. Kasaeian, Muktar Kedir, Y. Khader, Y. Khang, Daniel Kim, J. Leigh, S. Linn, R. Lunevicius, Hassan Razek, R. Malekzadeh, D. Malta, W. Marcenes, D. Markos, Y. Melaku, K. Meles, W. Mendoza, Desalegn Mengiste, T. Meretoja, T. Miller, K. Mohammad, A. Mohammadi, S. Mohammed, M. Moradi-Lakeh, G. Nagel, D. Nand, Q. Nguyen, S. Nolte, F. Ogbo, K. Oladimeji, E. Oren, Mahesh Pa, Eun‐Kee Park, David Pereira, D. Plass, M. Qorbani, A. Radfar, Anwar Rafay, Mahfuzar Rahman, S. Rana, K. Søreide, Maheswar Satpathy, M. Sawhney, S. Sepanlou, M. Shaikh, Jun She, I. Shiue, H. Shore, M. Shrime, S. So, S. Soneji, V. Stathopoulou, K. Stroumpoulis, M. Sufiyan, Bryan Sykes, R. Tabarés-Seisdedos, Fentaw Tadese, B. Tedla, G. Tessema, J. Thakur, B. Tran, K. Ukwaja, B. Uzochukwu, V. Vlassov, E. Weiderpass, Mamo Terefe, Henock Yebyo, H. Yimam, N. Yonemoto, M. Younis, Chuanhua Yu, Z. Zaidi, M. Zaki, Z. Zenebe, C. Murray, M. Naghavi (2017)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study
JAMA Oncology, 3
J. Monzon, A. Hay, Gail McDonald, J. Pater, R. Meyer, E. Chen, Bingshu Chen, J. Dancey (2015)Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
European journal of cancer, 51 17
P. Johnson, S. Qin, Joong-Won Park, R. Poon, J. Raoul, P. Philip, Chih-Hung Hsu, Tsung‐Hui Hu, J. Heo, Jianming Xu, Ligong Lu, Y. Chao, E. Boucher, K. Han, S. Paik, J. Robles-Aviña, M. Kudo, Lunan Yan, A. Sobhonslidsuk, D. Komov, T. Decaens, W. Tak, L. Jeng, David Liu, R. Ezzeddine, I. Walters, A. Cheng (2013)Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 28
David Lunn, D. Spiegelhalter, Andrew Thomas, N. Best (2009)The BUGS project: Evolution, critique and future directions
Statistics in Medicine, 28
A. El-Khoueiry, B. Sangro, T. Yau, T. Crocenzi, M. Kudo, Chiun Hsu, Tae-You Kim, S. Choo, J. Trojan, T. Welling, T. Meyer, Yoon-Koo Kang, W. Yeo, A. Chopra, Jeffrey Anderson, C. Cruz, Lixin Lang, J. Neely, Hao Tang, H. Dastani, I. Melero (2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, 389
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
The New England journal of medicine, 366 26
M. Jennewein, M. Lewis, Dawen Zhao, E. Tsyganov, N. Slavine, Jin He, L. Watkins, V. Kodibagkar, S. O’kelly, P. Kulkarni, P. Antich, A. Hermanne, F. Rösch, R. Mason, P. Thorpe (2008)Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine
Clinical Cancer Research, 14
M. Gray, J. Gong, M. Hatch, V. Nguyen, C. Hughes, J. Hutchins, B. Freimark (2016)Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers
Breast Cancer Research : BCR, 18
Sangheun Lee, B. Kim, S. Kim, J. Park, D. Kim, S. Ahn, K. Han (2015)Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Journal of Hepatocellular Carcinoma, 2
J. Bruix, A. Cheng, G. Meinhardt, K. Nakajima, Yoriko Sanctis, J. Llovet (2017)Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Journal of hepatology, 67 5
J. Llovet, M. Ducreux, R. Lencioni, A. Bisceglie, P. Galle, J. Dufour, T. Greten, E. Raymond, T. Roskams, T. Baère, V. Mazzaferro, M. Bernardi, J. Bruix, M. Colombo, A. Zhu (2012)EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
European journal of cancer, 48 5
U. Gaipl, Thomas Beyer, I. Baumann, R. Voll, C. Stach, P. Heyder, J. Kalden, A. Manfredi, M. Herrmann (2003)Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal--implications for antiphospholipid syndrome and systemic lupus erythematosus.
Immunobiology, 207 1
J. Barendregt, W. Nusselder, L. Bonneux (1997)Global burden of disease
The Lancet, 350
M. Kudo (2017)Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update
S. Wilhelm, Christopher Carter, L. Tang, D. Wilkie, Angela Mcnabola, H. Rong, Charles Chen, Xiaomei Zhang, P. Vincent, M. McHugh, Yichen Cao, Jaleel Shujath, S. Gawlak, Deepa Eveleigh, B. Rowley, Li Liu, Lila Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. Post, G. Bollag, P. Trail (2004)BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Cancer Research, 64
R. Finn, S. Qin, K. Han, F. Piscaglia, A. Baron, Joong-Won Park, G. Han, J. Jassem, Jean Blanc, A. Vogel, D. Komov, TR Evans, C. Lopez, C. Dutcus, M. Guo, Kenichi Saito, S. Kraljevic, T. Tamai, M. Ren, A. Cheng (2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet, 391
A. Zhu, Joon-Oh Park, B. Ryoo, C. Yen, R. Poon, D. Pastorelli, J. Blanc, H. Chung, A. Baron, T. Pfiffer, T. Okusaka, K. Kubáčková, J. Trojan, J. Sastre, I. Chau, Shao-chun Chang, P. Abada, Ling Yang, J. Schwartz, M. Kudo (2015)Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
The Lancet. Oncology, 16 7
A. Cheng, Yoon-Koo Kang, Zhendong Chen, C. Tsao, S. Qin, Jun Kim, R. Luo, Jifeng Feng, S. Ye, Tsai‐Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jie-jun Wang, W. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, Z. Guan (2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
The Lancet. Oncology, 10 1
N. Azad, J. Aragon-Ching, W. Dahut, M. Gutierrez, W. Figg, Lokesh Jain, S. Steinberg, M. Turner, E. Kohn, H. Kong (2009)Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Clinical Cancer Research, 15
DL Daleke (2003)Regulation of transbilayer plasma membrane phospholipid asymmetry
J Lipid Res, 44
M. Plummer, N. Best, K. Cowles, K. Vines (2006)CODA: convergence diagnosis and output analysis for MCMC
R. Voll, M. Herrmann, Edith Roth, C. Stach, J. Kalden, I. Girkontaitė (1997)Immunosuppressive effects of apoptotic cells
A. Mokdad, A. Singal, A. Yopp (2016)Advances in Local and Systemic Therapies for Hepatocellular Cancer
Current Oncology Reports, 18
Xiaoyun Cheng, Li Li, P. Thorpe, A. Yopp, R. Brekken, Xianming Huang (2016)Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts
Annals of Surgical Oncology, 23
S. Ran, A. Downes, P. Thorpe (2002)Increased exposure of anionic phospholipids on the surface of tumor blood vessels.
Cancer research, 62 21
A. Cheng, Yoon-Koo Kang, D. Lin, Joong-Won Park, M. Kudo, S. Qin, H. Chung, Xia Song, Jianming Xu, G. Poggi, M. Omata, S. Lowenthal, S. Lanzalone, Liqiang Yang, M. Lechuga, E. Raymond (2013)Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 32
P. Galle, A. Forner, J. Llovet, V. Mazzaferro, F. Piscaglia, J. Raoul, P. Schirmacher, V. Vilgrain (2018)EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
Journal of hepatology, 69 1
B. Freimark, J. Gong, D. Ye, M. Gray, V. Nguyen, S. Yin, M. Hatch, C. Hughes, A. Schroit, J. Hutchins, R. Brekken, Xianming Huang (2016)Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma
Cancer Immunology Research, 4
T. Luster, Jin He, Xianming Huang, S. Maiti, A. Schroit, P. Groot, P. Thorpe (2006)Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells*
Journal of Biological Chemistry, 281
AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu (2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Lancet Lond Engl., 389
M. Fukudo, Takuma Ito, T. Mizuno, K. Shinsako, E. Hatano, S. Uemoto, T. Kamba, Toshinari Yamasaki, O. Ogawa, H. Seno, T. Chiba, K. Matsubara (2014)Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
Clinical Pharmacokinetics, 53
J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. Blanc, A. Oliveira, A. Santoro, J. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. Greten, P. Galle, J. Seitz, I. Borbath, D. Häussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix (2008)Sorafenib in advanced hepatocellular carcinoma.
The New England journal of medicine, 359 4
V. Fadok, D. Bratton, A. Konowal, Peter Freed, J. Westcott, P. Henson (1998)Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF.
The Journal of clinical investigation, 101 4
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
The New England journal of medicine, 366 26
J He, Y Yin, TA Luster, L Watkins, PE Thorpe (2009)Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma
Clin Cancer Res Off J Am Assoc Cancer Res., 15
Jin He, Yi Yin, T. Luster, L. Watkins, P. Thorpe (2009)Antiphosphatidylserine Antibody Combined with Irradiation Damages Tumor Blood Vessels and Induces Tumor Immunity in a Rat Model of Glioblastoma
Clinical Cancer Research, 15
D. Daleke (2003)Regulation of transbilayer plasma membrane phospholipid asymmetry Published, JLR Papers in Press, December 16, 2002. DOI 10.1194/jlr.R200019-JLR200
Journal of Lipid Research, 44
Lili Gu, Huiling Liu, Linlin Fan, Y. Lv, Z. Cui, Yan Luo, Yuanyuan Liu, Guang-hu Li, Changping Li, Jun Ma (2014)Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis
Journal of Cancer Research and Clinical Oncology, 140
Jin He, T. Luster, P. Thorpe (2007)Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids
Clinical Cancer Research, 13
C. Căinap, S. Qin, Wen‐Tsung Huang, I. Chung, H. Pan, Ying Cheng, M. Kudo, Yoon-Koo Kang, Pei‐Jer Chen, H. Toh, V. Gorbunova, F. Eskens, J. Qian, M. McKee, J. Ricker, D. Carlson, S. El-Nowiem (2015)Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 2
R. Team (2014)R: A language and environment for statistical computing.
MSOR connections, 1
J. Llovet, M. Ducreux, R. Lencioni, A. Bisceglie, J. Dufour, T. Greten, E. Raymond, T. Roskams, V. Mazzaferro, J. Bruix, M. Colombo, A. Zhu (2012)EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
Journal of hepatology, 56 4
S Riedl, B Rinner, M Asslaber, H Schaider, S Walzer, A Novak (2011)In search of a novel target?Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy
Biochim Biophys Acta BBA Biomembr, 1808
S. Faivre, E. Raymond, E. Boucher, J. Douillard, Ho Lim, Jun Kim, M. Zappa, S. Lanzalone, Xun Lin, S. Deprimo, C. Harmon, A. Ruiz-Garcia, M. Lechuga, A. Cheng (2009)Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
The Lancet. Oncology, 10 8
JG Monzon, AE Hay, GT McDonald, JL Pater, RM Meyer, E Chen (1990)Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome
Eur J Cancer Oxf Engl, 2015
Background Bavituximab, an immunomodulator, targets phosphatidylserine (PS), a membrane lipid externalized on tumor and endothelial cells in response to sorafenib. Objective The objective of this phase II study was to assess the efficacy of combination bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC). Methods In this single-arm phase II study, patients with HCC determined to be unresectable with Eastern Cooperative Oncology Group (ECOG) score ≤ 2, Child–Pugh score A/B7 received intravenous bavituximab 3 mg/kg weekly and oral sorafenib 400 mg twice daily until disease progression or intolerable toxicity. We investigated time to progression (TTP) for patients receiving combination bavituximab and sorafenib compared with that for sorafenib-only historical controls. Results In total, 38 patients were accrued. The median follow-up was 6.1 months. Patient characteristics were as follows: median age 61 years; male 82%; hepatitis C virus 79%; Black 39%, Hispanic 26%, White 29%; previous treatment 39%; mac- rovascular invasion 84%; and extrahepatic metastases 24%. The median TTP was 6.7 months (95% confidence interval [CI] 4–17). The median overall survival was 6.1 months (95% CI 5–8), and the median disease-specific survival was 8.6 months (95% CI 6–14). Two patients experienced partial responses; none had a complete response. The disease control rate was 58%. Treatment-related adverse events were observed
Targeted Oncology – Springer Journals
Published: Aug 19, 2019
Access the full text.
Sign up today, get DeepDyve free for 14 days.